Wellbutrin SR, Zyban appeal
Executive Summary
GlaxoSmithKline's appeal of non-infringement rulings for Andrx' generic versions of bupropion products Wellbutrin SR and Zyban will be heard Dec. 2 in D.C. federal appeals court. Miami federal court issued summary judgement of non-infringement Feb. 28. Andrx said blend uniformity issues that prevented FDA approval of bupropion ANDAs have been addressed (1"The Pink Sheet" July 15, p. 7)....
You may also be interested in...
Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches
SkyePharma has waived its 180-day exclusivity for a generic version of Elan's Naprelan (naproxen), clearing the way for approval of Andrx' generic version of the product, Andrx says
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.